Nature has published their April 2022 Biopharma Dealmakers collection on the Advances in Artificial Intelligence-Driven ...
On a journey to drastically speed up cell therapy manufacturing, Kytopen lands $30M Series A
Spun out of an MIT lab, sitting in an office space above a Cambridge tapas restaurant from world-renowned chef Ken Oring ...
London-based health startup snaps up £2M to turbocharge diagnostics development with clinically validated home testing
The complexity of health and disease cannot be captured by a singular diagnostic test and therefore can’t be expected to ...
SELECTED PORTFOLIO COMPANIES
meet the team
Risk Warning
Don’t invest unless you’re prepared to lose money. This is a high‑risk investment. You may not be able to access your money easily and are unlikely to be protected if something goes wrong.